Quality of life in patients treated for COVID-19–associated mucormycosis at a tertiary care hospital

Pragya Kumar; Rajath Rao UR; Nilanjan Roy; Deepika Agrawal; Shamshad Ahmad; Kranti Bhavana

doi:10.24171/j.phrp.2022.0307

추천

검색

자료유형: 학술저널

저자정보: Pragya Kumar (Department of Community and Family Medicine All India Institute of Medical Sciences) Rajath Rao UR (Department of Community and Family Medicine All India Institute of Medical Sciences) Nilanjan Roy (Department of Community and Family Medicine All India Institute of Medical Sciences) Deepika Agrawal (Department of Community and Family Medicine All India Institute of Medical Sciences) Shamshad Ahmad (Department of Community and Family Medicine All India Institute of Medical Sciences) Kranti Bhavana (Department of Otorhinolaryngology All India Institute of Medical Sciences)

저널정보: 질병관리본부 Osong Public Health and Research Persptectives Osong Public Health and Research Perspectives 제14권 제2호

발행연도: 2023.4

수록면: 119 - 128 (10page)

DOI: 10.24171/j.phrp.2022.0307

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objectives: Coronavirus disease 2019 (COVID-19)–associated mucormycosis (CAM) has emerged as a formidable infection in patients with COVID-19. The aggressive management of CAM affects quality of life (QOL); thus, this study was designed to assess the QOL in patients with CAM at a tertiary healthcare institution.Methods: This cross-sectional study of 57 patients with CAM was conducted over 6 months using a semi-structured standard questionnaire (the abbreviated World Health Organization Quality of Life questionnaire [WHO-BREF]) and a self-rated improvement (SRI) scale ranging from 0 to 9. Cut-off values of ≤52 and <7 were considered to indicate poor QOL and poor improvement, respectively. The correlations of QOL and SRI scores were evaluated using Spearman rho values.Results: In total, 27 patients (47.4%; 95% confidence interval [CI], 34.9%–60.1%) and 26 patients (45.6%; 95% CI, 33.4%–58.4%) had poor QOL and poor SRI scores, respectively. The overall median (interquartile range) QOL score was 52 (41–63). Headache (adjusted B, −12.3), localized facial puffiness (adjusted B , −16.4), facial discoloration (adjusted B, −23.4), loosening of teeth (adjusted B, −18.7), and facial palsy (adjusted B, −38.5) wer e significantly associated with the QOL score in patients with CAM.Conclusion: Approximately 1 in 2 patients with CAM had poor QOL and poor improvement. Various CAM symptoms were associated with QOL in these patients. Early recognition is the key to optimal treatment, improved outcomes, and improved QOL in patients with CAM.

#Comorbidity #Mucormycosis #Pandemics #Quality of life #Vaccination

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!